Placental growth factor testing for suspected pre-eclampsia: a cost-effectiveness analysis.

<bold>Objective: </bold>To calculate the cost-effectiveness of implementing PlGF testing alongside a clinical management algorithm in maternity services in the UK, compared with current standard care.<bold>Design: </bold>Cost-effectiveness analysis.<bold>Setting: </bold>Eleven maternity units participating in the PARROT stepped-wedge cluster-randomised controlled trial.<bold>Population: </bold>Women presenting with suspected pre-eclampsia between 20+0 and 36+6  weeks' gestation.<bold>Methods: </bold>Monte Carlo simulation utilising resource use data and maternal adverse outcomes.<bold>Main Outcome Measures: </bold>Cost per maternal adverse outcome prevented.<bold>Results: </bold>Clinical care with PlGF testing costs less than current standard practice and resulted in fewer maternal adverse outcomes. There is a total cost-saving of UK£149 per patient tested, when including the cost of the test. This represents a potential cost-saving of UK£2,891,196 each year across the NHS in England.<bold>Conclusions: </bold>Clinical care with PlGF testing is associated with the potential for cost-savings per participant tested when compared with current practice via a reduction in outpatient attendances, and improves maternal outcomes. This economic analysis supports a role for implementation of PlGF testing in antenatal services for the assessment of women with suspected pre-eclampsia.<bold>Tweetable Abstract: </bold>Placental growth factor testing for suspected pre-eclampsia is cost-saving and improves maternal outcomes. [ABSTRACT FROM AUTHOR]